SI0812844T1 - Use of theophyllin derivatives for the treatment and prophylaxis fo shock conditions, novel xanthine compounds and processes for the production thereof - Google Patents

Use of theophyllin derivatives for the treatment and prophylaxis fo shock conditions, novel xanthine compounds and processes for the production thereof

Info

Publication number
SI0812844T1
SI0812844T1 SI9730414T SI9730414T SI0812844T1 SI 0812844 T1 SI0812844 T1 SI 0812844T1 SI 9730414 T SI9730414 T SI 9730414T SI 9730414 T SI9730414 T SI 9730414T SI 0812844 T1 SI0812844 T1 SI 0812844T1
Authority
SI
Slovenia
Prior art keywords
prophylaxis
processes
treatment
production
shock conditions
Prior art date
Application number
SI9730414T
Other languages
English (en)
Slovenian (sl)
Inventor
Ulrich Dr. Gebert
Erhard Dr. Wolf
Elisabeth Dr. Defossa
Uwe Dr. Heinelt
Hiristo Db. Anagnostopulos
Karl Dr. Rudolphi
John J. Dr. Grome
Original Assignee
Hoechst Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19622737A external-priority patent/DE19622737A1/de
Priority claimed from DE1996129815 external-priority patent/DE19629815A1/de
Application filed by Hoechst Aktiengesellschaft filed Critical Hoechst Aktiengesellschaft
Publication of SI0812844T1 publication Critical patent/SI0812844T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI9730414T 1996-06-07 1997-06-03 Use of theophyllin derivatives for the treatment and prophylaxis fo shock conditions, novel xanthine compounds and processes for the production thereof SI0812844T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19622737A DE19622737A1 (de) 1996-06-07 1996-06-07 Verwendung von Theophyllinderivaten zur Behandlung und Prophylaxe von Schockzuständen, neue Xanthinverbindungen und Verfahren zu deren Herstellung
DE1996129815 DE19629815A1 (de) 1996-07-24 1996-07-24 Verwendung von Theophyllinderivaten zur Behandlung und Prophylaxe von Schockzuständen, neue Xanthinverbindungen und Verfahren zu deren Herstellung
EP97108870A EP0812844B1 (de) 1996-06-07 1997-06-03 Verwendung von Theophyllinderivaten zur Behandlung und Propylaxe von Schockzuständen, neue Xanthinverbindungen und Verfahren zu deren Herstellung

Publications (1)

Publication Number Publication Date
SI0812844T1 true SI0812844T1 (en) 2003-02-28

Family

ID=26026372

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9730414T SI0812844T1 (en) 1996-06-07 1997-06-03 Use of theophyllin derivatives for the treatment and prophylaxis fo shock conditions, novel xanthine compounds and processes for the production thereof

Country Status (26)

Country Link
US (1) US6214992B1 (pl)
EP (1) EP0812844B1 (pl)
JP (1) JP4156687B2 (pl)
KR (1) KR100477177B1 (pl)
CN (1) CN1066146C (pl)
AR (1) AR007506A1 (pl)
AT (1) ATE226583T1 (pl)
AU (1) AU712277B2 (pl)
BR (1) BR9703499A (pl)
CA (1) CA2207120C (pl)
CZ (1) CZ292205B6 (pl)
DE (1) DE59708533D1 (pl)
DK (1) DK0812844T3 (pl)
ES (1) ES2185837T3 (pl)
HU (2) HU224958B1 (pl)
ID (1) ID19469A (pl)
IL (1) IL120997A (pl)
MX (1) MX9704203A (pl)
MY (1) MY117910A (pl)
NO (1) NO312400B1 (pl)
NZ (1) NZ328017A (pl)
PL (1) PL186576B1 (pl)
PT (1) PT812844E (pl)
RU (1) RU2201930C2 (pl)
SI (1) SI0812844T1 (pl)
TW (1) TW520285B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
FR2804958B1 (fr) * 2000-02-15 2005-07-08 Hoechst Marion Roussel Inc Derives de xanthine, leur procede de preparation et les intermediaires de ce procede, leur application comme medicament et les compositions pharmaceutiques les renfermant
FR2804867B1 (fr) * 2000-02-15 2002-09-20 Hoechst Marion Roussel Inc Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
CN101538224A (zh) * 2002-05-31 2009-09-23 先灵公司 制备黄嘌呤磷酸二酯酶v抑制剂及其前体的方法
SI1509525T1 (sl) * 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
CN112500413B (zh) * 2020-10-13 2024-03-01 安徽中医药大学 一类黄嘌呤芳酸醚衍生物，其制备方法及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735898A (en) 1985-07-16 1988-04-05 The University Of Virginia Alumini Patents Foundation Monoclonal antibodies and method of identifying species using the same
US4904472A (en) * 1987-04-10 1990-02-27 The University Of Virginia Alumni Patent Foundation Use of adenosine antagonists in the treatment of bradyarrhythmias and mechanical dysfunction associated with cardiopulmonary resuscitation
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
JPH03167186A (ja) * 1989-11-24 1991-07-19 Hokuriku Seiyaku Co Ltd キサンチン誘導体及びその用途
US5036683A (en) * 1990-06-04 1991-08-06 Geuvjehizian Moushegh Y Steering wheel lock protector
DE4019571A1 (de) 1990-06-20 1992-01-02 Hoechst Ag Pharmazeutische kombinationspraeparate enthaltend cephalosporin- und xanthinderivate und deren verwendung
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
CN1066146C (zh) 2001-05-23
CA2207120C (en) 2007-05-08
IL120997A (en) 2001-06-14
HUP9701016A3 (en) 2004-11-29
EP0812844A3 (de) 1998-04-08
BR9703499A (pt) 1998-10-06
MY117910A (en) 2004-08-30
TW520285B (en) 2003-02-11
HU0500865D0 (en) 2005-11-28
IL120997A0 (en) 1997-11-20
HU224958B1 (en) 2006-04-28
PL186576B1 (pl) 2004-01-30
RU2201930C2 (ru) 2003-04-10
PT812844E (pt) 2003-03-31
AR007506A1 (es) 1999-11-10
CZ174397A3 (en) 1997-12-17
CA2207120A1 (en) 1997-12-07
JP4156687B2 (ja) 2008-09-24
DE59708533D1 (de) 2002-11-28
EP0812844B1 (de) 2002-10-23
CN1169993A (zh) 1998-01-14
NZ328017A (en) 2001-05-25
JPH1059969A (ja) 1998-03-03
KR980008230A (ko) 1998-04-30
HU225040B1 (en) 2006-05-29
MX9704203A (es) 1998-04-30
NO972582L (no) 1997-12-08
PL320413A1 (en) 1997-12-08
AU712277B2 (en) 1999-11-04
ATE226583T1 (de) 2002-11-15
CZ292205B6 (cs) 2003-08-13
DK0812844T3 (da) 2003-02-17
EP0812844A2 (de) 1997-12-17
NO972582D0 (no) 1997-06-06
HU9701016D0 (en) 1997-07-28
US6214992B1 (en) 2001-04-10
ES2185837T3 (es) 2003-05-01
NO312400B1 (no) 2002-05-06
KR100477177B1 (ko) 2005-09-30
ID19469A (id) 1998-07-16
HUP9701016A2 (hu) 1998-12-28
AU2469897A (en) 1997-12-11

Similar Documents

Publication Publication Date Title
EP0715851A3 (en) Substituted phenylpyrimidine derivatives useful in the treatment or prevention of diseases of the central nervous system
HU913664D0 (en) Process for the production of indian- and kinoline derivatives
IL110204A0 (en) Novel indolene derivatives, processes for their preparation and their use for the treatment of cns disorders
SG43952A1 (en) Process for the purification of chlorofluorocarbons
SG47910A1 (en) Continuous process for the production of methionine or methionine derivatives
EP0510503A3 (en) Process for the treatment of surfaces
SI0812844T1 (en) Use of theophyllin derivatives for the treatment and prophylaxis fo shock conditions, novel xanthine compounds and processes for the production thereof
HU911984D0 (en) Process for the production of dialkyl piridine-2,3-diacarboxylate and its derivatives
HU9200129D0 (en) Process for the production of sulphonamide derivatives
AU9024591A (en) Biphenylalkyl xanthine compounds for treatment of cardiovascular disorders
HU910937D0 (en) Process for the production of 8-sulfamylethylene-2-amino-tetraline derivatives
HU9201260D0 (en) Process for the production of new indole- and dihydrokinoline derivatives
IL110015A0 (en) Processes for the preparation of pyranyl derivatives
EP0507458A3 (en) Process for the purification of 1,1,1,2-tetrafluoroethane
AU8096094A (en) Use of nicotine substitutes for the treatment of nicotine withdrawal
IL97772A0 (en) Processes for the manufacture of 2-deoxy-d-threo-pentofuranose derivatives,and 2-deoxy-pentofuranose derivatives
ZA975018B (en) Use of theophylline derivatives for the treatment and prophylaxis of states of shock, novel xanthine compounds and processes for their preparation.
EP0641764A3 (de) Verfahren zur Herstellung von Hydroxyalkylaminonitrobenzol-Derivaten.
HU908372D0 (en) Process for the production of rifamycin derivatives
IL110662A0 (en) Process for the manufacture of phenoxyphenoxyalkyl derivatives
HU9200288D0 (en) Process for the production of heterocyclic amodo-prostaglanide analogues
HU9502738D0 (en) Process for the preparation of condensed carbapeneme derivatives
GB9116206D0 (en) Process for the reduction of halocarbons
GB2284417B (en) Process for the production of spherulitic nitroguanidine
GB9107312D0 (en) Process for the treatment of effluent